WISDOMTREE TRUST MODERN TECH PLATFORMS FUND PLAT 深 沪
已收盘 10-20 16:00:00 美东时间
30.4929
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 30.4929
- 总市值 914.79万
- 52周最高 34.9989
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 23.838
- 委 比 0.00%
- 总股本 30.00万
- 历史最高 49.7773
- 量 比 0
- 振 幅 0.00%
- 历史最低 19.6608
- 每 手 1
- 风险率 0.34%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Harley-Davidson Is Recalling 88,039 US Motorcycles As Airbox Backplate Breather Port Maybe Blocked, Allowing Pressure Build Up Inside Crankcase- NHTSA
BRIEF-Harley-Davidson Is Recalling 88,039 US Motorcycles As Airbox Backplate Breather Port Maybe Blocked, Allowing Pressure Build Up Inside Crankcase- NHTSA May 1 (Reuters) - Harley-Davidson Inc HOG.N : HARLEY-DAVIDSON IS RECALLING 88039 US MOTORCYCLES AS AIRBOX BACKPLATE BREATHER PORT MAYBE BLOCKED
05-01 15:14
BRIEF-Daiichi Sankyo Co Ltd - Ifinatamab Deruxtecan Granted Priority Review In The U.S. For Adult Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Who Experienced Disease Progression On Or After Platinum-Based Chemotherapy
BRIEF-Daiichi Sankyo Co Ltd - Ifinatamab Deruxtecan Granted Priority Review In The U.S. For Adult Patients With Previously Treated Extensive-Stage Small Cell Lung Cancer Who Experienced Disease Progression On Or After Platinum-Based Chemotherapy April 14 (Reuters) - Daiichi Sankyo Co Ltd 4568.T : DA
04-14 09:14
BRIEF-NN Announces Acquisition To Further Growth In Electric Grid And Data Center
BRIEF-NN Announces Acquisition To Further Growth In Electric Grid And Data Center NN Inc NNBR.O : NN ANNOUNCES ACQUISITION TO FURTHER GROWTH IN ELECTRIC GRID AND DATA CENTER NN INC - EXPECTS NEW PLATING CAPABILITY OPERATIONAL IN FALL 2026 NN INC - GUIDES $70 MILLION-$80 MILLION NEW BUSINESS WINS IN
03-27 20:03
BRIEF-FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer
BRIEF-FDA Approves Relacorilant With NAB-Paclitaxel For Platinum-Resistant Epithelial Ovarian, Fallopian Tube,Primary Peritoneal Cancer March 25 (Reuters) - US FDA: FDA APPROVES RELACORILANT WITH NAB-PACLITAXEL FOR PLATINUM-RESISTANT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER F
03-25 22:59
BRIEF-American Express Launches New Graphite Business Cash Unlimited Card
BRIEF-American Express Launches New Graphite Business Cash Unlimited Card March 25 (Reuters) - American Express Co AXP.N : AMERICAN EXPRESS: LAUNCHES NEW GRAPHITE BUSINESS CASH UNLIMITED CARD AMERICAN EXPRESS: BUSINESS MEMBERSHIP TO EXPAND WITH EIGHT NEW PRODUCTS, BENEFITS, AI-POWERED CAPABILITIES F
03-25 19:00
BRIEF-Eli Lilly's Retatrutide Showed Significant Reductions In A1C & Weight In TRANSCEND-T2D-1 Trial
BRIEF-Eli Lilly's Retatrutide Showed Significant Reductions In A1C & Weight In TRANSCEND-T2D-1 Trial March 19 (Reuters) - Eli Lilly and Co LLY.N : ELI LILLY: RETATRUTIDE SHOWED SIGNIFICANT REDUCTIONS IN A1C & WEIGHT IN FIRST PHASE 3 TRIAL FOR TYPE 2 DIABETES TREATMENT ELI LILLY: RETATRUTIDE LOWERED
03-19 18:45
Platinum Industries Plans Virtual One-on-One Meeting With Investor 11H Advisors
Platinum Industries Limited ( ($IN:PLATIND) ) has shared an update. Platinum In...
03-11 20:39
BRIEF-Reliance Subsidiary AMI Metals Awarded Significant Government Infrastructure And Defense Projects
BRIEF-Reliance Subsidiary AMI Metals Awarded Significant Government Infrastructure And Defense Projects March 10 (Reuters) - Reliance Inc RS.N : RELIANCE, INC. SUBSIDIARY AMI METALS, INC. AWARDED SIGNIFICANT GOVERNMENT INFRASTRUCTURE AND DEFENSE PROJECTS RELIANCE INC - AMI METALS AWARDED MULTI-YEAR
03-10 18:53
Platinum Industries Schedules Investor Meeting, Stresses Regulatory Compliance
Platinum Industries Limited ( ($IN:PLATIND) ) has issued an announcement. Plati...
03-04 00:49
Veru Inc. Publishes Corporate Presentation on Enobosarm-GLP-1 Obesity Program and Sabizabulin Atherosclerosis Development
Veru Inc. Publishes Corporate Presentation on Enobosarm-GLP-1 Obesity Program and Sabizabulin Atherosclerosis Development Veru Inc. outlined its cardiometabolic pipeline, highlighting enobosarm, an oral selective androgen receptor modulator, being developed in combination with a GLP-1 receptor agoni
03-02 22:39
